Everything below concerns Heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
An enzyme-linked immunosorbent assay (ELISA) is one of the most common ways for detecting anti-U1 RNP antibodies in patient sera. In this procedure, purified or recombinant U1-RNP antigens are placed into microplate wells. After nonspecific binding sites are blocked, diluted patient serum is added to the wells and incubated. If specific autoantibodies are present, they can bind to the immobilized antigen. A secondary enzyme-conjugated anti-human IgG antibody is added, that it is followed by a substrate that produces a color change. This is read by spectrophotometry and compared to a standard curve to measure the levels of antibodies. Reference ranges are specific to each laboratory, and results must be interpreted in the context of clinical findings. This method is highly sensitive and frequently used to support diagnosis in patients with suspected MCTD or other connective tissue diseases. Other laboratory techniques include immunoblotting, immunoprecipitation, and multiplex immunoassays. Immunoblotting identifies antibodies directed against specific proteins within the U1 snRNP complex, while immunoprecipitation has traditionally been considered one of the most specific methods for confirming anti-U1 RNP antibodies. Multiplex immunoassays allow laboratories to detect several extracellular nuclear antigen antibodies at the same time, making them useful for evaluating those with suspected autoimmune diseases.
== Treatment == There has been too little experience on the treatment of LECT2 amyloidosis to establish recommendations other than offering methods to support kidney function and dialysis. Nonetheless, it is important to accurately diagnose ALECT2-based amyloid disease in order to avoid treatment for other forms of amyloidosis.
is the rate of mass transfer into the gas phase, Dc is the average diffusion coefficient of free aroma molecules in the emulsion, Agc is the surface area of the gas/food interface, tc is the time that the surface elements are exposed to the surface, and
Sources: en.wikipedia.org
Portugal, officially the Portuguese Republic, is a country in Southwestern Europe. Mainland Portugal is located on the southwestern portion of the Iberian Peninsula, and bordered by Spain to the north and east. Portugal also includes the archipelagos of Madeira and the Azores in the Atlantic Ocean. The country has a population of 11.4 million, and Lisbon, its capital, is the largest city. Portugal's internal waters and territorial sea together account for two-fifths of its territory, and its exclusive economic zone is one of Europe's largest. The country's terrain contains a diverse range of landscapes and regional climates. The western Iberian Peninsula has been inhabited since prehistory, with the earliest signs of settlement dating to between 5500 BC and 5300 BC. Muslims had occupied the Iberian Peninsula since 711. As a result of the Reconquista against them, Portugal was established as a county of the Kingdom of León in 868 and formally as a kingdom in 1179. During the Age of Discovery, the kingdom made several advancements in nautical science and maritime exploration to discover new territories and sea routes, which led to the establishment of the Portuguese Empire. The kingdom became a republic in 1910, before becoming a dictatorship in 1926, whose 1974 overthrow enabled democracy to be established in 1976. Portugal is a unitary republic and multi-party representative democracy with four separate sovereignty organs: president, government, parliament, and judiciary.
=== Iron chelation === Multiple blood transfusions lead to severe iron overload, as the body eventually breaks down the hemoglobin in donated cells. This releases iron which it is unable to excrete. Iron overload may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox. Deferoxamine is only effective as a daily injection, complicating its long-term use. Adverse effects include primary skin reactions around the injection site and hearing loss. Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea.
epitope Also antigenic determinant. The specific site or region within an antigenic macromolecule such as a protein or carbohydrate which is recognized by B or T cells of the immune system, against which a specific antibody is produced, and with which the antibody's paratope specifically interacts or binds. In proteins, epitopes are typically motifs of 4–5 amino acid residues, sequential or discontiguous, which by virtue of the distinct spatial conformation they adopt upon protein folding are able to uniquely interact with a particular paratope. In this sense they may be considered binding sites, though they do not necessarily overlap with ligand binding sites and need not be in any way relevant to the protein's normal function. Very large molecules may have multiple epitopes, each of which is recognized by a different antibody.
Sources: en.wikipedia.org
==== Public opinion ==== Despite its growing notoriety in some circles, media stories generally suggest that the public at large are still mostly unaware of salvia, with the majority perhaps having never even heard of it. Although published responses may not necessarily be representative of public opinion as a whole, some news agencies generally support reader and viewer feedback in connection with their stories.
Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are extracted from the patient, genetically engineered to recognize tumor-specific antigens, and returned to the patient. Cell types that can be used in this way are natural killer (NK) cells, lymphokine-activated killer cells, cytotoxic T cells, and dendritic cells. Finally, specific antibodies can be developed that recognize cancer cells and target them for destruction by the immune system. Examples of such antibodies include rituximab (targeting CD-20), trastuzumab (targeting HER-2), and cetuximab (targeting EGFR). Passive antibody therapies aim to increase the activity of the immune system without specifically targeting cancer cells. For example, cytokines directly stimulate the immune system and increase immune activity. Checkpoint inhibitors target proteins (immune checkpoints) that normally dampen the immune response. This enhances the ability of the immune system to attack cancer cells. Current research is identifying new potential targets to enhance immune function. Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab.
Timber can be dried to any desired low moisture content by conventional or solar kiln drying, but in air drying, moisture contents of less than 18% are difficult to attain for most locations. The drying times are considerably less in conventional kiln drying than in solar kiln drying, followed by air drying. This means that if capital outlay is involved, this capital sits for a longer time when air drying is used. On the other hand, installing, operating and maintaining an industrial kiln is expensive. In addition, wood that is being air dried takes up space, which could also cost money. In air drying, there is little control over the drying conditions, so drying rates cannot be controlled. The temperatures employed in kiln drying typically kill all the fungi and insects in the wood if a maximum dry-bulb temperature of above 60°C is used for the drying schedule. This is not guaranteed in air drying. If air drying is done improperly (exposed to the sun), the rate of drying may be overly rapid in the dry summer months, causing cracking and splitting, and too slow during the cold winter months. Significant advantages of conventional kiln drying include higher throughput and better control of the final moisture content. Conventional kilns and solar drying both enable wood to be dried to any moisture content regardless of weather conditions. For most large-scale drying operations solar and conventional kiln drying are more efficient than air drying. Compartment-type kilns are most commonly used in timber companies.
=== Tunable vacuum ultraviolet (VUV) === The vacuum ultraviolet (V‑UV) band (100–200 nm) can be generated by non-linear 4 wave mixing in gases by sum or difference frequency mixing of 2 or more longer wavelength lasers. The generation is generally done in gasses (e.g. krypton, hydrogen which are two-photon resonant near 193 nm) or metal vapors (e.g. magnesium). By making one of the lasers tunable, the V‑UV can be tuned. If one of the lasers is resonant with a transition in the gas or vapor then the V‑UV production is intensified. However, resonances also generate wavelength dispersion, and thus the phase matching can limit the tunable range of the 4 wave mixing. Difference frequency mixing (i.e., f1 + f2 − f3) has an advantage over sum frequency mixing because the phase matching can provide greater tuning. In particular, difference frequency mixing two photons of an ArF (193 nm) excimer laser with a tunable visible or near IR laser in hydrogen or krypton provides resonantly enhanced tunable V‑UV covering from 100 nm to 200 nm. Practically, the lack of suitable gas / vapor cell window materials above the lithium fluoride cut-off wavelength limit the tuning range to longer than about 110 nm. Tunable V‑UV wavelengths down to 75 nm was achieved using window-free configurations.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.